| Drug Name |
Zoledronic acid |
| Drug ID |
BADD_D02392 |
| Description |
Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120]
Zoledronic acid was granted FDA approval on 20 August 2001.[L13712] |
| Indications and Usage |
For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget’s Disease. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
M05BA08 |
| DrugBank ID |
DB00399
|
| KEGG ID |
D01968
|
| MeSH ID |
D000077211
|
| PubChem ID |
68740
|
| TTD Drug ID |
D0VM2L
|
| NDC Product Code |
70860-802; 43598-255; 42533-102; 67457-794; 65797-0006; 65129-1144; 55111-688; 0078-0435; 67457-920; 50742-416; 55150-266; 54288-100; 55111-685; 0409-4215; 60505-6110; 16714-815; 68001-437; 55150-283; 25021-830; 65372-1117; 25021-826; 14593-836; 16729-242; 0143-9642; 57741-2600; 51991-065; 68001-366; 68083-142; 53104-7622; 25021-801; 43598-331; 17478-324; 70860-210; 63323-966; 68554-0037; 43598-330; 63126-906; 63759-0012; 62147-0125; 67457-619; 68083-116; 63850-7104; 68083-256; 17478-327; 68083-135; 63323-961; 67457-390 |
| Synonyms |
Zoledronic Acid | 2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid | CGP 42446A | CGP-42446 | CGP 42446 | CGP42446 | CGP-42'446 | CGP42'446 | CGP 42'446 | Zometa | Zoledronic Acid Anhydrous | Zoledronate |
